問卷

TPIDB > Search Result

Search Result

篩選

Study Statistics

5576Cases

20022027

Total

5576

  • I

    615

  • I/II

    269

  • II

    1305

  • II/III

    138

  • III

    2775

  • IV

    109

  • Others

    363

List

5576Cases

2020-04-01 - 2024-06-12

Phase II/III

Completed
A 52-Week, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Crohn’s Disease (INTREPID Lead-In)
  • Condition/Disease

    Severely Active Crohn’s Disease

  • Test Drug

    Brazikumab (AMG 139)

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting6Sites

2005-06-01 - 2006-12-01

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2007-04-30 - 2008-09-04

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2009-07-01 - 2010-07-31

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2007-05-31 - 2008-09-15

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites